Phase II trial of VEGF [vascular endothelial growth factor] Trap [aflibercept] in patients with metastatic breast cancer previously treated with anthracycline and/or taxane.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2013
At a glance
- Drugs Aflibercept (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 05 Jan 2011 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
- 05 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.